MCID: MCL006
MIFTS: 52

Macular Retinal Edema

Categories: Cardiovascular diseases, Eye diseases

Aliases & Classifications for Macular Retinal Edema

MalaCards integrated aliases for Macular Retinal Edema:

Name: Macular Retinal Edema 12 15 72
Macular Edema 12 37 55 15
Macular Edema, Cystoid 72

Classifications:



External Ids:

Disease Ontology 12 DOID:4449
KEGG 37 H01651
MeSH 44 D008269
NCIt 50 C35468
SNOMED-CT 68 37231002
UMLS 72 C0024440 C0271051

Summaries for Macular Retinal Edema

KEGG : 37
Macular edema is a common feature of many diseases of the retina, such as intraocular inflammation (uveitis), central or branch retinal vein occlusion, diabetic retinopathy and following cataract extraction. It is characterized by a retinal thickening in the macular area due to the breakdown of the blood-retinal barrier. Extracellular fluid accumulates in the intraretinal area or collects in the subretinal space. In more severe cases, it occurs as cystoid edema with the typical petaloid appearance, and is the leading cause of visual loss. New treatments for macular edema have emerged over the past decade, the most recent and efficacious of which have involved blockage of vascular endothelial growth factor (VEGF) by frequent intravitreal injection of pharmacologic agents.

MalaCards based summary : Macular Retinal Edema, also known as macular edema, is related to diabetic macular edema and retinal vein occlusion, and has symptoms including edema and peau d'orange. An important gene associated with Macular Retinal Edema is VEGFA (Vascular Endothelial Growth Factor A), and among its related pathways/superpathways are p70S6K Signaling and Human cytomegalovirus infection. The drugs Acetazolamide and Pioglitazone have been mentioned in the context of this disorder. Affiliated tissues include eye, endothelial and retina, and related phenotypes are reproductive system and vision/eye

Related Diseases for Macular Retinal Edema

Diseases related to Macular Retinal Edema via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 382)
# Related Disease Score Top Affiliating Genes
1 diabetic macular edema 33.0 VEGFA PRKCB IL6 ICAM1 CCL2
2 retinal vein occlusion 32.1 VEGFA IL6 CCL2
3 vitreous detachment 32.0 VEGFA KCNMA1
4 endophthalmitis 31.7 VEGFA MRAP ICAM1
5 macular holes 31.4 VEGFA KCNMA1 CCL2
6 background diabetic retinopathy 31.2 VEGFA INS
7 kuhnt-junius degeneration 31.2 VEGFA PGF
8 neovascular glaucoma 31.2 VEGFA PGF
9 anterior uveitis 31.1 IL6 CCL2
10 severe nonproliferative diabetic retinopathy 31.0 VEGFA INS
11 microvascular complications of diabetes 1 30.8 VEGFA INS ICAM1 CCL2
12 microvascular complications of diabetes 5 30.7 VEGFA PRKCB PGF INS ICAM1
13 poems syndrome 30.5 VEGFA IL6
14 vascular disease 30.4 VEGFA INS IL6 CCL2
15 cancer-associated retinopathy 30.3 VEGFA PGF
16 retinal vascular disease 30.2 VEGFA PGF INS ICAM1 CCL2
17 retinal disease 30.2 PDE6A CRB1 BEST1
18 sleep apnea 30.0 INS IL6 ICAM1
19 rubeosis iridis 30.0 VEGFA INS FANCG
20 retinal vascular occlusion 29.9 VEGFA PGF FANCG CCL2
21 optic disk drusen 29.9 VEGFA KCNMA1 CRB1
22 cerebrovascular disease 29.9 INS IL6 ICAM1
23 retinal telangiectasia 29.8 VEGFA CRB1
24 macular dystrophy, dominant cystoid 29.4 VEGFA PRKCB PDE6A MRAP MAK CRB1
25 nervous system disease 29.3 VEGFA INS IL6 CCL2
26 arteriosclerosis 29.1 INS IL6 ICAM1 CCL2
27 macular degeneration, age-related, 1 28.9 VEGFA PGF KCNMA1 FANCG CRB1 CCL2
28 myocardial infarction 28.3 VEGFA PGF INS IL6 ICAM1 CCL2
29 retinitis pigmentosa 11.7
30 hydrops, lactic acidosis, and sideroblastic anemia 11.6
31 pars planitis 11.6
32 vitreoretinopathy, neovascular inflammatory 11.6
33 vitreoretinochoroidopathy 11.4
34 bestrophinopathy, autosomal recessive 11.4
35 retinitis pigmentosa 83 11.2
36 cataract 11.1
37 central retinal vein occlusion 11.0
38 uveitis 11.0
39 retinal detachment 10.9
40 microvascular complications of diabetes 2 10.8
41 neuroretinitis 10.8
42 retinitis 10.8
43 yemenite deaf-blind hypopigmentation syndrome 10.7
44 ocular hypertension 10.6
45 retinal ischemia 10.6
46 posterior uveitis 10.5
47 intermediate uveitis 10.5
48 panuveitis 10.5
49 hyperglycemia 10.5
50 retinal microaneurysm 10.4

Graphical network of the top 20 diseases related to Macular Retinal Edema:



Diseases related to Macular Retinal Edema

Symptoms & Phenotypes for Macular Retinal Edema

UMLS symptoms related to Macular Retinal Edema:


edema, peau d'orange

MGI Mouse Phenotypes related to Macular Retinal Edema:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 reproductive system MP:0005389 9.5 BEST1 FANCG IL6 INS KCNMA1 MAK
2 vision/eye MP:0005391 9.23 BEST1 CRB1 ICAM1 IL6 INS PDE6A

Drugs & Therapeutics for Macular Retinal Edema

Drugs for Macular Retinal Edema (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 333)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetazolamide Approved, Vet_approved Phase 4 59-66-5 1986
2
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
3
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
4
Linagliptin Approved Phase 4 668270-12-0 10096344
5
Bevacizumab Approved, Investigational Phase 4 216974-75-3
6
Homatropine Approved Phase 4 87-00-3
7
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
8
Loteprednol Approved, Experimental Phase 4 129260-79-3, 82034-46-6 444025 9865442
9
Indomethacin Approved, Investigational Phase 4 53-86-1 3715
10
Travoprost Approved Phase 4 157283-68-6 5282226
11
Interferon beta-1a Approved, Investigational Phase 4 145258-61-3 6438354
12
Interferon beta-1b Approved Phase 4 145155-23-3
13
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
14
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
15
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
16
Bromfenac Approved Phase 4 91714-94-2 60726
17
Oxymetazoline Approved, Investigational Phase 4 1491-59-4 4636
18
Ephedrine Approved Phase 4 299-42-3 9294
19
Phenylephrine Approved Phase 4 59-42-7 6041
20
Pseudoephedrine Approved Phase 4 90-82-4 7028
21
Difluprednate Approved Phase 4 23674-86-4 443936
22
Fluprednisolone Approved Phase 4 53-34-9
23
Verteporfin Approved, Investigational Phase 4 129497-78-5
24
Gatifloxacin Approved, Investigational Phase 4 112811-59-3 5379
25
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
26
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
27
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
28
Polyestradiol phosphate Approved Phase 4 28014-46-2
29
Nepafenac Approved, Investigational Phase 4 78281-72-8 151075
30
Dipivefrin Approved Phase 4 52365-63-6 3105
31
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
32
Povidone-iodine Approved Phase 4 25655-41-8
33
Povidone Approved Phase 4 9003-39-8
34
Iodine Approved, Investigational Phase 4 7553-56-2 807
35
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
36
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
37
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
38
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
39
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 126941
40
leucovorin Approved Phase 4 58-05-9 143 6006
41
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
42
Glimepiride Approved Phase 4 93479-97-1 3476
43
Empagliflozin Approved Phase 4 864070-44-0
44
Histidine Approved, Nutraceutical Phase 4 71-00-1 6274
45
Tretinoin Approved, Investigational, Nutraceutical Phase 4 302-79-4 5538 444795
46
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 22737-96-8, 11103-57-4, 68-26-8 9904001 445354
47
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
48
2,4-thiazolidinedione Investigational Phase 4 2295-31-0
49 Cloprostenol Vet_approved Phase 4 54276-21-0
50
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7

Interventional clinical trials:

(show top 50) (show all 876)
# Name Status NCT ID Phase Drugs
1 POSTERIOR SUB-TENON'S CAPSULE INJECTION OF BEVACIZUMAB FOR TREATMENT OF DIFFUSE DIABETIC MACULAR EDEMA Unknown status NCT00567372 Phase 4 bevacizumab (Sub-tenon´s injection)
2 Analysis of Cytokines in Response to Treatment of Diabetic Macular Edema With 0.3mg Lucentis Unknown status NCT03097068 Phase 4 Lucentis
3 Combined Treatment of Intravitreous Bevacizumab and Triamcinolone for the Treatment or Macular Edema Secondary to Central Retinal Vein Occlusion Unknown status NCT00566761 Phase 4 bevacizumab and triamcinolone
4 Phase 4 Study of Intravitreal Aflibercept Injection for Recalcitrant Central Retinal Vein Occlusion Associated Macular Edema Despite Prior Anti-Vascular Endothelial Growth Factor (VEGF) Therapy. (ARChiMEDES) Unknown status NCT01857544 Phase 4 Aflibercept
5 Phase 4 Comparison of the Effects of Bevacizumab Before vs After Pattern Panretinal Photocoagulation Unknown status NCT00804206 Phase 4 bevacizumab;bevacizumab
6 Evaluation of an Additional Therapeutic Approach to Diabetic Macular Edema by Combining Standard Therapy (Intravitreal Injection of a VEGF-inhibitor) With Micropulse Diode Laser Treatment in a Randomized, Controlled Proof of Concept Study Unknown status NCT02059772 Phase 4 ranibizumab
7 A Single Arm, Single Dose Study to Evaluate the Effect of Intravitreal Dexamethasone Implant (Ozurdex®) on Hard Exudates of Diabetic Macular Edema Unknown status NCT02399657 Phase 4 Intravitreal dexamethasone 0.7mg implant
8 Predictors of Treatment Response to Aflibercept and Aqueous Cytokine Levels in Patients With Persistent Diabetic Macular Edema Following Treatment With Ranibizumab: An Interventional Prospective Study Unknown status NCT02651168 Phase 4
9 Effect of Aflibercept (Eylea®) in the Management of Bevacizumab (Avastin®) Resistant Diabetic Macular Edema Unknown status NCT02924987 Phase 4 Aflibercept Injection
10 The Effect of Bevacizumab on Peripheral Retinal Changes as Imaged by Wide -Field Fluorescein Angiography in Diabetic Macular Edema Unknown status NCT02096874 Phase 4 Bevacizumab
11 Panretinal Photocoagulation for Proliferative Diabetic Retinopathy in a Single Session Using Low Fluence Parameters Unknown status NCT01023698 Phase 4
12 To Compare the Efficacy of Monotherapy With Anti-Vascular Endothelial Growth Factor (Ranibizumab or Bevacizumab) Versus Combination Therapy With Anti-Vascular Endothelial Growth Factor and End-point-management Grid Laser Photocoagulation for Diabetic Macular Edema Unknown status NCT02462304 Phase 4 ranibizumab;Bevacizumab
13 Evaluation of the "Treat-and-extend" Scheme in Patients With Retinal Vein Occlusion (RVO) With and Without LASER Treatment of Ischaemic Retinal Areas Unknown status NCT02522897 Phase 4 Ranibizumab
14 Treatment of Cystoid Macular Edema in Patients With Retinal Degeneration Unknown status NCT00716586 Phase 4 dorzolamide
15 Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Unknown status NCT01827722 Phase 4 Ozurdex;Ranibizumab;Combination Ozurdex with Ranibizumab PRN
16 Randomized Trial Comparing Injection Frequency Between Aflibercept and Ranibizumab in Patients With Central Retinal Vein Occlusion With a Treat and Extend Algorithm Unknown status NCT02274259 Phase 4 Aflibercept;Ranibizumab
17 The Effects of Thiazolidinedione on the Diabetic Retinopathy and Nephropathy Unknown status NCT01175486 Phase 4 Actos (Pioglitazone);Acarbose
18 Longterm Efficiency and Safety of Intravitreal Injections With Bevacizumab in Patients With Neovascularisation or Macular Edema Unknown status NCT03211741 Phase 4 Bevacizumab Injection [Avastin]
19 A One-year Randomized Controlled Trial Evaluating the Impact of Pioglitazone Versus Linagliptin on Bone Turnover Markers Unknown status NCT02429232 Phase 4 Pioglitazone;Linagliptin
20 Effects of Ranibizumab to Delay or Regression Non-proliferative Diabetic Retinopathy(NPDR) With DME Assessed by Microaneurysm Changes: A Pilot Study Unknown status NCT02834663 Phase 4 Lucentis
21 A Pilot Study to Determine if Intravitreal Injections of Pegaptanib Sodium (Macugen) Given Every 12 Weeks for a Year After an Induction Phase of Three Injections Every 6 Weeks Will Reduce the Progression of Proliferative Diabetic Retinopathy in Patients Without Significant Vitreous Hemorrhage in Comparison to Treatment With Retinal Photocoagulation Alone and After an Induction Phase Unknown status NCT01486771 Phase 4 Macugen ® (pegaptanib sodium)
22 Topical Application of ACULAR a Randomized, Vehicle Controlled Clinical Trial: Efficiency in Inhibiting Proliferative Retinopathy of Prematurity Unknown status NCT00634972 Phase 4 ACULAR;REFRESH TEARS;placebo
23 Three Arm, Prospective, Single-blind, Randomized Study Comparing Ranibizumab Plus Green Diode Laser Versus Ranibizumab Plus Pattern Scan Laser (Pascal) Versus Ranibizumab (Monotherapy) for Proliferative Diabetic Retinopathy. Unknown status NCT02005432 Phase 4 Intravitreal Ranibizumabe;panfotocoagulation (PASCAL);panfotocoagulation (PRP) single shoot (ETDRS)
24 EFFECTS OF IMMEDIATE ARGON LASER PERIPHERAL IRIDOPLASTY Versus CONVENTIONAL SYSTEMIC MEDICAL THERAPY ON OPTIC NERVE HEAD STRUCTURE AND FUNCTION OF ACUTE PRIMARY ANGLE CLOSURE EYES Unknown status NCT00485238 Phase 4 Intravenous acetazolamide
25 Pattern Scan Laser System vs Regular Photocoagulation System: Changes in Macular Edema Post Treatment. Unknown status NCT00563628 Phase 4
26 Pattern Scan Laser System vs Regular Photocoagulation System: Changes in Electroretinograms and Contrast Sensitivity Post Treatment. Unknown status NCT00563043 Phase 4
27 Intraoperative Dexamethasone Implant (Ozurdex®) Improves Outcome of Cataract Surgery in Patients With Diabetic Macular Edema Completed NCT01546402 Phase 4 Dexamethasone Drug delivery system (Ozurdex)
28 Evaluation of ReAding Speed, Contrast Sensitivity, and Work Productivity in Working Individuals With Diabetic Macular Edema Following Treatment With Intravitreal Ranibizumab Completed NCT02107131 Phase 4 Intravitreal ranibizumab 0.3mg
29 An Open-label, Prospective, Multicentre, Uncontrolled, Proof of Concept Study Assessing the Efficacy of Lucentis (Ranibizumab) Administered by an Individualized "Treat and Extend" Dosing Regimen in Patients With Visual Impairment Due to Diabetic Macular Edema Completed NCT01297569 Phase 4 Ranibizumab
30 A Safety and Efficacy Study of OZURDEX® in Macular Edema Associated With Branch Retinal Vein Occlusion Completed NCT01903720 Phase 4 dexamethasone implant
31 Prevention of Post-Photocoagulation Macular Edema by Intravitreal Bevacizumab. Completed NCT00801866 Phase 4 Bevacizumab
32 Randomized Clinical Trial Comparing Prophylactic Nepafenac 0.1% and Ketorolac 0.5% Versus Placebo in Preventing Postoperative Macular Edema After Uncomplicated Phacoemulsification Cataract Extraction (PNK) Completed NCT01395069 Phase 4 Nepafenac 0.1%;Ketorolac 0.5%
33 A Randomized, Parallel Group, Masked Clinical Study to Evaluate the Efficacy of Triamcinolone and Bevacizumab Through Intravitreal Injection With Individual or Simultaneous Drugs to Treatment of Diabetic Macular Edema Completed NCT00737971 Phase 4 Bevacizumab intravitreal;Triamcinolone;Triamcinolone + Bevacizumab
34 A Non-Randomized, Open-Label, Single Center Phase 4 Study of the Effect and Safety of ILUVIEN® in Chronic Diabetic Macular Edema Patients Considered Insufficiently Responsive to Available Therapies (Laser, Anti-VEGF) With or Without Intravitreal Corticosteroid Therapy Completed NCT02472366 Phase 4 ILUVIEN
35 An Open-label, Multicenter, Phase IV Study of the Efficacy and Safety of Ranibizumab 0.5mg in Diabetic Patients Presenting a Visual Impairment Due to Macular Edema in Current Medical Practice Completed NCT01315275 Phase 4 Ranibizumab
36 A Single Masked, Randomized Controlled Study to Assess Efficacy of Ozurdex as Adjunct to Avastin Compared With Avastin Alone in the Treatment of Patients With Diabetic Macular Edema Completed NCT01309451 Phase 4 Bevacizumab;dexamethasone intravitreal implant
37 Open-label Phase-4 Study to Examine the Change of Vision-related Quality of Life in Subjects With Diabetic Macular Edema (DME) During Treatment With Intravitreal Injections of 2 mg Aflibercept According to EU Label for the First Year of Treatment Completed NCT02581995 Phase 4 Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)
38 Peripheral and Macular Retinal Vascular Perfusion and Leakage Dynamics in Diabetic Macular Edema and Retinal Venous Occlusions During Intravitreal Aflibercept Injection (IAI) Treatment for Retinal Edema: PERMEATE Study Completed NCT02503540 Phase 4 Aflibercept
39 Open Label Macugen for the Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion Completed NCT00406107 Phase 4 pegaptanib sodium (Macugen)
40 TAHOE: Sustained InTravitreal DexAmetHasone Implant (Ozurdex) for Uveitic Macular Edema Completed NCT01870440 Phase 4 Ozurdex Intravitreal Injection (0.7 mg)
41 Ozurdex for Diabetic Macular Edema Treated With Pars Plana vitrEctomy and Membrane RemovAl (OPERA Study) Completed NCT01613716 Phase 4 Ozurdex
42 A 10 Month, Single Masked, Randomized Controlled Study to Assess Anti-VEGF Alone Versus Ozurdex Given Every 3 Months for Treatment of Persistent Diabetic Macular Edema Completed NCT02036424 Phase 4 Ozurdex;Bevacizumab
43 A Non-randomised, Open-label, Multicenter Phase 4 Pilot Study on the Effect and Safety of Iluvien® in Chronic Diabetic Macular Edema Patients Considered Insufficiently Responsive to Available Therapies With or Without Intravitreal Corticosteroid Therapy (RESPOND) Completed NCT02359526 Phase 4 IlUVIEN
44 Central Macular Thickness, Macular Electroretinogram, and Visual Acuity in Patients With Diabetic Macular Edema After Intravitreal Aflibercept Injection. A One Month Pre-Post Intervention Follow Up Study Completed NCT03453281 Phase 4 Aflibercept Injection [Eylea]
45 Twelve Months Experience With a Dexamethasone-implant for the Treatment of Macular Edema Associated With Retinal Vein Occlusion Completed NCT01767545 Phase 4 Dexamethasone implant;Bevacizumab
46 Treat and Extend Versus Dosing Every Eight Weeks With Intravitreal Aflibercept Injections for the Treatment of Diabetic Macular Edema (EVADE Study) Completed NCT02392364 Phase 4 Intravitreal Aflibercept Injection
47 Treatment of Acute Pseudophakic Cystoid Macular Edema: Bromfenac 0.09% Versus Diclofenac Sodium 0.1% Versus Ketorolac Tromethamine 0.5% Completed NCT00595543 Phase 4 Bromfenac;Ketorolac;Diclofenac
48 Dexamethasone Intravitreal Implant (0.7mg) for the Treatment of Persistent Diabetic Macular Edema Following Intravitreal Anti-Vascular Endothelial Growth Factor Therapy Completed NCT02471651 Phase 4 Dexamethasone intravitreal implant (0.7 mg);Intravitreal anti-VEGF injection
49 Chilean Interventional Open Label Pilot Study, to Assess the Efficacy and Safety of Lucentis® (Ranibizumab Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema. Completed NCT02140411 Phase 4 Ranibizumab Intravitreal injections
50 Long-Term Efficacy and Safety of Intravitreal Aflibercept Injections for the Treatment of Diabetic Macular Edema in Subjects Who Completed the Three Year VISTA-DME Trial (The Endurance 2 Trial) Completed NCT02368756 Phase 4 Aflibercept

Search NIH Clinical Center for Macular Retinal Edema

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Flurbiprofen
Flurbiprofen sodium

Genetic Tests for Macular Retinal Edema

Anatomical Context for Macular Retinal Edema

MalaCards organs/tissues related to Macular Retinal Edema:

41
Eye, Endothelial, Retina, Testes, Bone, Brain, Monocytes

Publications for Macular Retinal Edema

Articles related to Macular Retinal Edema:

(show top 50) (show all 9048)
# Title Authors PMID Year
1
A more efficient ocular delivery system of triamcinolone acetonide as eye drop to the posterior segment of the eye. 38
30835587 2019
2
MicroRNAs as biomarkers of diabetic retinopathy and disease progression. 38
31290435 2019
3
Retinal proteome associated with bradykinin-induced edema. 38
31351056 2019
4
Correlation between metamorphopsia and disorganization of the retinal inner layers in eyes with diabetic macular edema. 38
31227899 2019
5
Intravitreal sustained-release dexamethasone implant for the treatment of persistent cystoid macular edema in ocular syphilis. 38
31436209 2019
6
The impact of intravitreal dexamethasone implant (Ozurdex®) on retrobulbar hemodynamics in patients with diabetic macular edema and retinal vein occlusions. 38
30773934 2019
7
INVICTUS: intravitreal anti-VEGF and dexamethasone implant comparison for the treatment of diabetic macular edema: a 6 months follow-up Study. 38
30741468 2019
8
Role of PASCAL and optical coherence tomography angiograpgy in the treatment of diffuse unilateral subacute neuroretinitis caused by large live motile worm. 38
31436212 2019
9
Pars plana vitrectomy with intraoperative optical coherence tomography for sub-internal limiting membrane fibrosis excision in a child with Terson syndrome: Surgical and pathological correlation. 38
31198885 2019
10
Vitrectomy for a secondary epiretinal membrane following treatment of adult-onset Coats' disease. 38
31334386 2019
11
Classification of diabetes-related retinal diseases using a deep learning approach in optical coherence tomography. 38
31416547 2019
12
PHOTOCOAGULATION VERSUS RANIBIZUMAB FOR PROLIFERATIVE DIABETIC RETINOPATHY: Should Baseline Characteristics Affect Choice of Treatment? 38
30807516 2019
13
Screening eye exams in youth with type 1 diabetes under 18 years of age: Once may be enough? 38
31206973 2019
14
New imaging systems in diabetic retinopathy. 38
31203437 2019
15
Deciphering the role of circulating lncRNAs: RNCR2, NEAT2, CDKN2B-AS1, and PVT1 and the possible prediction of anti-VEGF treatment outcomes in diabetic retinopathy patients. 38
31327036 2019
16
Posterior Segment Complications and Impact on Long-Term Visual Outcomes in Eyes With a Type 1 Boston Keratoprosthesis. 38
31232746 2019
17
Ocular manifestations of pulmonary hypertension. 38
30849428 2019
18
Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial. 38
30905643 2019
19
Longitudinal Retinal Perfusion Status in Eyes with Diabetic Macular Edema Receiving Intravitreal Aflibercept or Laser in VISTA Study. 38
30946887 2019
20
Aqueous Humour Cytokine Changes with Intravitreal Dexamethasone Implant Injection for Diabetic Macular Edema. 38
31418610 2019
21
ETIOLOGY AND CLINICAL CHARACTERISTICS OF MACULAR EDEMA IN PATIENTS WITH FAMILIAL EXUDATIVE VITREORETINOPATHY. 38
31404032 2019
22
Macular function following intravitreal ranibizumab for macular edema associated with branch retinal vein occlusion. 38
30980231 2019
23
Prognostic role of optical coherence tomography after switch to dexamethasone in diabetic macular edema. 38
31375899 2019
24
Cystoid macular edema following selective laser trabeculoplasty in a patient with ocular hypertension. 38
30105491 2019
25
Role of Cytokines in Ranibizumab Therapy for Macular Edema in Patients with Central Retinal Vein Occlusion. 38
31373873 2019
26
Bilateral and symmetric postoperative cystoid macular edema in a patient with macular telangiectasia type 2 after uneventful subsequent phacoemulsification procedures. 38
31133418 2019
27
Anti-VEGF versus dexamethasone implant (Ozurdex) for the management of Centre involved Diabetic Macular Edema (CiDME): a randomized study. 38
31377905 2019
28
Inner Nuclear Layer Cystic Changes in Phakic Fellow Eyes of Patients With Acute Pseudophakic Cystoid Macular Edema. 38
31415701 2019
29
Combination of Grid Laser Photocoagulation and a Single Intravitreal Ranibizumab as an Efficient and Cost-Effective Treatment Option for Macular Edema Secondary to Branch Retinal Vein Occlusion. 38
30444191 2019
30
Effect of Intravitreal Anti-Vascular Growth Factor Agents With or Without Macular Photocoagulation on Diabetic Macular Edema: A Systematic Review and Meta-Analysis. 38
31079358 2019
31
Combination of intravitreal bevacizumab and erythropoietin versus intravitreal bevacizumab alone for refractory diabetic macular edema: a randomized double-blind clinical trial. 38
31401683 2019
32
Intravitreal dexamethasone implant Ozurdex® in the treatment of diabetic macular edema in patients not previously treated with any intravitreal drug: A prospective 12-month follow-up study. 38
31378087 2019
33
Macular Abnormalities in Vogt-Koyanagi-Harada Disease. 38
31415220 2019
34
NEW PROPOSAL FOR THE PATHOPHYSIOLOGY OF TYPE 3 NEOVASCULARIZATION AS BASED ON MULTIMODAL IMAGING FINDINGS. 38
30550528 2019
35
Retinal Defects Three Months After Intravitreal Dexamethasone Implant. 38
31415706 2019
36
Outcomes of Using Sutureless, Scleral-Fixated Posterior Chamber Intraocular Lenses. 38
31390915 2019
37
Current practice in the management of branch retinal vein occlusion in Japan: Survey results of retina specialists in Japan. 38
31428900 2019
38
[Clinical analysis of juxtapapillary retinal capillary hemangioma]. 38
31422640 2019
39
Incidence of Irvine Gass Syndrome after Phacoemulsification with Spectral-Domain Optical Coherence Tomography. 38
31414913 2019
40
Oxymetazoline: reduction of subconjunctival hemorrhage incidence after intravitreal injections. 38
31358153 2019
41
Changes in intraocular pressure after intravitreal fluocinolone acetonide (ILUVIEN): real-world experience in three European countries. 38
30242062 2019
42
Effect of Baseline Subretinal Fluid on Treatment Outcomes in VIVID-DME and VISTA-DME Studies. 38
31103642 2019
43
[Baseline diagnostics and initial treatment decision for anti-vascular endothelial growth factor treatment in retinal diseases : Comparison between results by study physician and reading centers (ORCA/OCEAN study)]. 38
30367231 2019
44
Low health literacy levels in patients with chronic retinal disease. 38
31395040 2019
45
Clinical efficacy and safety of ranibizumab in the treatment of wet age-related macular degeneration. 38
31180279 2019
46
Intravitreal Dexamethasone Implant for Treatment of Sarcoidosis-Related Uveitis. 38
31140122 2019
47
Multimodal Retinal Imaging Findings in Williams-Beuren Syndrome. 38
31415699 2019
48
Projection-Resolved Optical Coherence Tomographic Angiography of Retinal Plexuses in Retinitis Pigmentosa. 38
30849344 2019
49
The Value of Automated Diabetic Retinopathy Screening with the EyeArt System: A Study of More Than 100,000 Consecutive Encounters from People with Diabetes. 38
31335200 2019
50
Diagnostic Accuracy of Community-Based Diabetic Retinopathy Screening With an Offline Artificial Intelligence System on a Smartphone. 38
31393538 2019

Variations for Macular Retinal Edema

Expression for Macular Retinal Edema

Search GEO for disease gene expression data for Macular Retinal Edema.

Pathways for Macular Retinal Edema

Pathways related to Macular Retinal Edema according to GeneCards Suite gene sharing:

(show all 26)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.84 PRKCB PGF INS IL6 CCL2
2
Show member pathways
12.77 VEGFA PRKCB IL6 ICAM1 CCL2
3
Show member pathways
12.7 PRKCB MRAP KCNMA1 INS
4 12.59 VEGFA PRKCB PGF INS
5
Show member pathways
12.56 VEGFA PRKCB PGF INS
6
Show member pathways
12.47 VEGFA PRKCB ICAM1 CCL2
7
Show member pathways
12.18 VEGFA PRKCB ICAM1 CCL2
8
Show member pathways
12.09 INS IL6 ICAM1 CCL2
9 11.92 VEGFA ICAM1 CCL2
10 11.89 VEGFA INS IL6
11
Show member pathways
11.88 PGF IL6 ICAM1 CCL2
12 11.8 IL6 ICAM1 CCL2
13 11.75 IL6 ICAM1 CCL2
14
Show member pathways
11.73 PRKCB INS IL6
15 11.61 VEGFA IL6 ICAM1 CCL2
16 11.49 VEGFA PRKCB INS IL6
17
Show member pathways
11.45 VEGFA IL6 ICAM1
18 11.3 IL6 ICAM1 CCL2
19 11.27 IL6 ICAM1 CCL2
20 11.23 VEGFA INS IL6
21 11.23 VEGFA IL6 ICAM1 CCL2
22 11.07 PRKCB IL6 ICAM1
23 11.02 ICAM1 CCL2
24 11.02 VEGFA PRKCB IL6 ICAM1 CCL2
25 10.88 VEGFA CCL2
26 10.74 ICAM1 CCL2

GO Terms for Macular Retinal Edema

Biological processes related to Macular Retinal Edema according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 cellular response to lipopolysaccharide GO:0071222 9.71 IL6 ICAM1 CCL2
2 positive regulation of angiogenesis GO:0045766 9.69 VEGFA PRKCB PGF
3 regulation of cell shape GO:0008360 9.67 VEGFA ICAM1 CCL2
4 cytokine-mediated signaling pathway GO:0019221 9.62 VEGFA IL6 ICAM1 CCL2
5 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.54 VEGFA IL6 ICAM1
6 positive regulation of protein autophosphorylation GO:0031954 9.52 VEGFA INS
7 positive regulation of vascular endothelial growth factor receptor signaling pathway GO:0030949 9.48 VEGFA PRKCB
8 eye photoreceptor cell development GO:0042462 9.46 VEGFA CRB1
9 response to hypoxia GO:0001666 9.46 VEGFA PGF KCNMA1 ICAM1
10 vascular endothelial growth factor signaling pathway GO:0038084 9.43 VEGFA PGF
11 induction of positive chemotaxis GO:0050930 9.4 VEGFA PGF
12 positive regulation of mast cell chemotaxis GO:0060754 9.26 VEGFA PGF
13 ovarian follicle development GO:0001541 9.13 VEGFA ICAM1 FANCG
14 positive regulation of NF-kappaB transcription factor activity GO:0051092 8.92 PRKCB INS IL6 ICAM1

Molecular functions related to Macular Retinal Edema according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 8.8 VEGFA PGF IL6

Sources for Macular Retinal Edema

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....